6:26 PM
 | 
Nov 05, 2009
 |  BC Extra  |  Clinical News

Vectibix misses OS endpoint for mCRC

Amgen Inc. (NASDAQ:AMGN) said first-line Vectibix panitumumab plus FOLFOX4 chemotherapy missed the secondary endpoint of significantly improving overall survival in patients with wild-type K-Ras (KRAS)...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >